These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 16890322

  • 1. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Yukiue H, Kobayashi Y, Yano M, Fujii Y.
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [Abstract] [Full Text] [Related]

  • 2. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y.
    Clin Cancer Res; 2005 Apr 15; 11(8):2924-9. PubMed ID: 15837743
    [Abstract] [Full Text] [Related]

  • 3. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, Matsumura A, Iuchi K, Haneda H, Suzuki E, Kobayashi Y, Yano M, Fujii Y.
    Int J Cancer; 2006 Jan 01; 118(1):180-4. PubMed ID: 16003726
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. EGFR polymorphism of the kinase domain in Japanese lung cancer.
    Sasaki H, Endo K, Takada M, Kawahara M, Tanaka H, Kitahara N, Matsumura A, Iuchi K, Kawaguchi T, Okuda K, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    J Surg Res; 2008 Aug 01; 148(2):260-3. PubMed ID: 18541260
    [Abstract] [Full Text] [Related]

  • 6. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M, Toyooka S, Ichihara S, Ohashi K, Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, Date H, Shimizu N.
    Lung Cancer; 2006 Jul 01; 53(1):117-21. PubMed ID: 16730855
    [Abstract] [Full Text] [Related]

  • 7. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS.
    J Clin Pathol; 2011 Nov 01; 64(11):947-52. PubMed ID: 21725039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ.
    Clin Cancer Res; 2005 Jun 15; 11(12):4289-94. PubMed ID: 15958609
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 15; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
    Lung Cancer; 2011 Jan 15; 71(1):65-9. PubMed ID: 20430469
    [Abstract] [Full Text] [Related]

  • 14. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.
    Clin Cancer Res; 2006 Jul 01; 12(13):3908-14. PubMed ID: 16818686
    [Abstract] [Full Text] [Related]

  • 15. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
    Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.
    Cancer Cytopathol; 2013 Oct 01; 121(10):552-60. PubMed ID: 23780873
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, Yano M, Fujii Y.
    Lung Cancer; 2009 Jun 01; 64(3):295-300. PubMed ID: 19058870
    [Abstract] [Full Text] [Related]

  • 17. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
    Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ.
    Lung Cancer; 2005 Oct 01; 50(1):25-33. PubMed ID: 16011858
    [Abstract] [Full Text] [Related]

  • 18. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K.
    Clin Cancer Res; 2006 Jul 01; 12(13):3915-21. PubMed ID: 16818687
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.